Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;13(6):1447-1469.
doi: 10.1007/s40122-024-00672-9. Epub 2024 Oct 28.

Abdominal Pain in Inflammatory Bowel Disease-Epidemiology, Pathophysiology, and Management: A Narrative Review

Affiliations
Review

Abdominal Pain in Inflammatory Bowel Disease-Epidemiology, Pathophysiology, and Management: A Narrative Review

Wei-Wei Tan et al. Pain Ther. 2024 Dec.

Abstract

Abdominal pain is a major symptom of inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, and has a significant impact on patients' quality of life. Given the evolving understanding of IBD pathology and management strategies, there is an urgent need to review the recent research findings. In this review, we have analyzed the epidemiology, pathophysiology, and management of abdominal pain in IBD over the past decade. We draw on the current literature and highlight emerging trends, challenges, and advances in this field. By synthesizing key findings, this review provides insights into the complex interplay between abdominal pain, disease progression, and therapeutic interventions for IBD.

Keywords: Abdominal pain; Crohn’s disease; Inflammatory bowel disease; Management; Pathophysiology; Ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Wei-wei Tan, Zi-xuan Liu, Xiao-Yan Liu, Wei-bing Zhang, Lie Zheng, Ya-Li Zhang, and Yan-Cheng Dai have nothing to disclose.

Figures

Fig. 1
Fig. 1
Pathophysiologic mechanisms of abdominal pain in inflammatory bowel disease (IBD). Transient Receptor Potential Vanilloid 1 (TRPV1); Acute inflammation and post-inflammation; Coexisting irritable bowel syndrome; Gut microbiota and metabolites
Fig. 2
Fig. 2
Suggestions for pain management with pharmacological treatment, non-pharmacological treatment, and psychological intervention for abdominal pain in inflammatory bowel disease (IBD)

References

    1. Xu L, He B, Sun Y, Li J, Shen P, Hu L, Liu G, Wang J, Duan L, Zhan S, Wang S. Incidence of inflammatory bowel disease in urban China: a nationwide population-based study. Clin Gastroenterol Hepatol. 2023;21(3379–3386):e3329. 10.1016/j.cgh.2023.08.013. - PubMed
    1. Long D. Crohn’s disease and ulcerative colitis: from pathophysiology to novel therapeutic approaches. Biomedicines. 2024. 10.3390/biomedicines12030689. - PMC - PubMed
    1. Zeitz J, Ak M, Muller-Mottet S, Scharl S, Biedermann L, Fournier N, Frei P, Pittet V, Scharl M, Fried M, Rogler G, Vavricka S, Swiss IBD. Pain in IBD patients: very frequent and frequently insufficiently taken into account. PLoS ONE. 2016;11: e0156666. 10.1371/journal.pone.0156666. - PMC - PubMed
    1. Coates MD, Johri A, Gorrepati VS, Maheshwari P, Dalessio S, Walter V, Stuart A, Koltun W, Bernasko N, Tinsley A, Williams ED, Clarke K. Abdominal pain in quiescent inflammatory bowel disease. Int J Colorectal Dis. 2021;36:93–102. 10.1007/s00384-020-03727-3. - PMC - PubMed
    1. Camilleri M, Lembo A, Katzka DA. Opioids in gastroenterology: treating adverse effects and creating therapeutic benefits. Clin Gastroenterol Hepatol. 2017;15:1338–49. 10.1016/j.cgh.2017.05.014. - PMC - PubMed

LinkOut - more resources